Lucie Curylova

Lucie Curylova

Auto-generated profile, based on publicly available information

Lucie Curylova

Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
PKPolina Kameneva
Polina Kameneva
VMVictoria I. Melnikova
Victoria I. Melnikova
MKMaria Eleni Kastriti
Maria Eleni Kastriti
AKAnastasia Igorevna Kurtova
Anastasia Igorevna Kurtova
EKEmil Kryukov
Emil Kryukov
IAIgor Adameyko
Igor Adameyko
Adrenal glands are the major organs releasing catecholamines and regulating our stress response. The mechanisms balancing generation of adrenergic chromaffin cells and protecting against neuroblastoma tumors are still enigmatic. Here we revealed that serotonin (5HT) controls the numbers of chromaffin cells by acting upon their immediate progenitor “bridge” cells via 5-hydroxytryptamine receptor 3A (HTR3A), and the aggressive HTR3Ahigh human neuroblastoma cell lines reduce proliferation in response to HTR3A-specific agonists. In embryos (in vivo), the physiological increase of 5HT caused a prolongation of the cell cycle in “bridge” progenitors leading to a smaller chromaffin population and changing the balance of hormones and behavioral patterns in adulthood. These behavioral effects and smaller adrenals were mirrored in the progeny of pregnant female mice subjected to experimental stress, suggesting a maternal-fetal link that controls developmental adaptations. Finally, these results corresponded to a size-distribution of adrenals found in wild rodents with different coping strategies.

4 December 2024 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
LCLucie Curylova
Lucie Curylova
IZIva Staniczkova Zambo
Iva Staniczkova Zambo
JNJakub Neradil
Jakub Neradil
MKMichal Kyr
Michal Kyr
NJNicola Jurackova
Nicola Jurackova
JSJan Skoda
Jan Skoda

22 January 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
LCLucie Curylova
Lucie Curylova
IZIva Staniczkova Zambo
Iva Staniczkova Zambo
JNJakub Neradil
Jakub Neradil
MKMichal Kyr
Michal Kyr
NJNicola Jurackova
Nicola Jurackova
JSJan Skoda
Jan Skoda
Pediatric sarcomas are bone and soft tissue tumors that often show high metastatic potential and refractory stem-like phenotypes with poor outcomes. Aggressive sarcomas frequently harbor disrupted p53 pathway. However, whether the abrogated p53 function associates with sarcoma stemness which might be targeted by p53 reactivation remains unclear. Here we show that aggressive stem-like sarcoma cells exhibit deregulated p53, making them vulnerable to drugs that restore the wild-type p53 activity. Immunohistochemistry in mice xenografts and human tumor tissues revealed that p53 deregulations together with the enhanced expression of SOX2 or KLF4 stemness-related transcription factors are crucial in the development of pediatric osteosarcoma, rhabdomyosarcoma, and Ewing’s sarcoma. Alteration of p53 function appears to be an important step for attaining a fully stem-like phenotype in sarcoma cells and p53-positive pediatric sarcomas show high frequency of early metastasis. Moreover, the reactivation of p53 via MDM2/MDMX inhibition selectively induces cell death in aggressive stem-like Ewing’s sarcoma cells, while sparing healthy fibroblasts. Collectively, our results demonstrate that restoration of p53 canonical activity may represent a promising strategy for improving therapy of pediatric sarcomas with unfavorable stem-like traits. HIGHLIGHTS SOX2 and KLF4 factors are crucially involved in pediatric sarcoma development Dysregulated p53 pathway predisposes sarcoma cells to a fully stem-like phenotype p53 positivity associates with early metastasis in pediatric sarcoma patients Restoring wild-type p53 activity selectively targets stem-like Ewing’s sarcomas